Objective:To produce a monoclonal antibody(mAb) against latent membrane protein 2A(LMP2A) with hybridoma technology and characterize its immune specificity. Methods:The spleen cells from BALB/c mice immunized with epitope fusion protein LMP2A were fused with SP2/0 cells to produce a monoclonal antibody against LMP2A. We further determined immuno-specificity of the purified antibody by various immunological assays such as ELISA,Western blotting assays,immunofluorescence,immunohistochemisty and FACS. Results:We successfully produced a hybridoma cell line,which continuously and stably secreted anti-LMP2A mAb. Moreover,this mAb can effectively recognize the transmembrane glycoprotein LMP2A over-expressed in nasopharyngeal carcinoma cells and tissues. Conclusion:We successfully obtained mouse anti-LMP2A mAb that can specifically recognize the transmembrane glycoprotein LMP2A in nasopharyngeal carcinoma cells. It can be potentially applied to early stage clinical diagnosis and some tumor targeted therapy.